{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:26:23Z","timestamp":1772191583628,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgmr.2024.101126","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:37:58Z","timestamp":1722022678000},"page":"101126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Avalglucosidase alfa in infantile-onset Pompe disease: A snapshot of real-world experience in Italy"],"prefix":"10.1016","volume":"40","author":[{"given":"Agata","family":"Fiumara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Sapuppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Crescitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenza","family":"Gragnaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101126_bb0005","series-title":"Pompe Disease: Glycogen Storage Disease type II, Acid Alpha-Glucosidase (Acid Maltase) Deficiency","author":"Reuser","year":"2018"},{"issue":"2","key":"10.1016\/j.ymgmr.2024.101126_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161 A","author":"Gungor","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2024.101126_bb0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3233\/JND-210784","article-title":"Motor responses in pediatric Pompe disease in the ADVANCE participant cohort","volume":"9","author":"Duong","year":"2022","journal-title":"J. Neuromusc. Dis."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2024.101126_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"issue":"13","key":"10.1016\/j.ymgmr.2024.101126_bb0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101126_bb0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"l. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefit of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2024.101126_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-022-01219-4","article-title":"Immune response to alglucosidase in infantile Pompe disease: reccomendations from an Italian pediatric expert panel","volume":"48","author":"Gragnaniello","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0045","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet.Med."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","article-title":"Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease","volume":"25","author":"Case","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.ymgmr.2024.101126_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/19768354.2022.2079719","article-title":"Mannose-6-phosphate glycan for lysosomal targeting: various applications from enzyme replacement therapy to lysosome-targeting chimeras","volume":"26","author":"Seo","year":"2022","journal-title":"Animal Cells System."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0060","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0065","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late- onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"12","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101126_bb0070","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of Avalglucosidase alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2024.101126_bb0075","article-title":"Efficacy and safety of Avalglucosidase alfa in patients with late-onset Pompe disease after 97WeeksA phase 3 randomized clinical trial","volume":"apr 10","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0080","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/j.gim.2022.01.566","article-title":"Mini-COMET: safety and efficacy of \u226597 weeks\u2019 avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa","volume":"24","author":"Kronn","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0085","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","author":"Kishnani","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0095","article-title":"Urine glucose tetrasaccharide: a good biomarker for glycogenoses type II and III? A study of the French cohort","volume":"23","author":"Pirauda","year":"2020","journal-title":"Mol. Genet. Metabol. Reports"},{"issue":"Suppl. 3","key":"10.1016\/j.ymgmr.2024.101126_bb0090","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1007\/s10545-010-9195-2","article-title":"Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report","volume":"33","author":"Del Rizzo","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0100","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.3390\/jcm10214828","article-title":"A systematic review and meta-analysis of enzyme replacement therapy in late-onset Pompe disease","volume":"10","author":"Dornelles","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0105","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2024.101126_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe consortium","volume":"6","author":"IAMs","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"issue":"3","key":"10.1016\/j.ymgmr.2024.101126_bb0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2024.101126_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","article-title":"Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase","volume":"269","author":"van Capelle","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","article-title":"Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease","volume":"380","author":"Scheffers","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet. Med."},{"issue":"20","key":"10.1016\/j.ymgmr.2024.101126_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204796","article-title":"Plasma Neurofilament light (NfL) in patients affected by Niemann-pick type C diseases (NPCD)","volume":"10","author":"Dardis","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101126_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-021-01817-1","article-title":"Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy","volume":"16","author":"Hsueh","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgmr.2024.101126_bb0155","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperon enhances blood a glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101126_bb0160","first-page":"S13","article-title":"Effects of repeat avalglucosidase dosing on ptosis in participants with infantile onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa","volume":"132","author":"Davison","year":"2022","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692400079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692400079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:35:52Z","timestamp":1723923352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221442692400079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":32,"alternative-id":["S221442692400079X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101126","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avalglucosidase alfa in infantile-onset Pompe disease: A snapshot of real-world experience in Italy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101126"}}